ClinicalThought™
Interact with experts and peers.

Recent Posts

10 of 47 Shown
  • ClinicalThought Discussions

    What Is the Best Approach in MDS When Hypomethylating Agents Fail?

    Jamile Shammo MD, FASCP, FACP - 5/1/2013
    Currently, there is no well-defined second-line or salvage therapy for these patients. Nevertheless, there are some data to guide use of available salvage regimens.
  • ClinicalThought Discussions

    Bladder Cancer: Are Changes in Chemotherapy Warranted?

    Derek Raghavan MD, PhD, FACP - 4/26/2013 3 comments / Last Comment: 5/5/2013
    The NCCN recently updated its guidelines for the use of chemotherapy in patients with bladder cancer. In this ClinicalThought, I explore which of these changes should definitely be applied in clinical practice and which I believe have only limited evidence to support them.
  • ClinicalThought Discussions

    How I Manage Patients With Relapsed/Refractory T-Cell Lymphomas

    Francine Foss MD - 4/25/2013 2 comments / Last Comment: 5/6/2013
    Once patients with T-cell lymphomas relapse, they can be very challenging to treat. In this post, I explore treatment options and provide recommendations for these patients.
  • ClinicalThought Discussions

    How Do We Improve Current Therapy for MCL? Here Are 4 Promising Possibilities

    James O. Armitage MD - 4/24/2013 1 comment / Last Comment: 5/15/2013
    Several recent reports of the incorporation of other drugs into the management of mantle cell lymphoma are encouraging and predict a brighter future.
  • ClinicalThought Discussions

    HER2-Positive Metastatic Breast Cancer: How Do You Present the Choices to Your Patient?

    Mohammad  Jahanzeb MD - 4/16/2013 8 comments / Last Comment: 5/16/2013
    With additional treatment options for trastuzumab-resistant/refractory HER2-positive metastatic breast cancer, come new challenges in presenting their complexities to patients. In this post, I offer my perspective on framing the patient-centered discussion.
  • ClinicalThought Discussions

    MPACT Study: Finally, Some Good News in Pancreatic Cancer

    Alan P. Venook MD - 4/3/2013 3 comments / Last Comment: 4/25/2013
    For 17 years, no agent has been shown to improve survival by more than 1 month when combined with gemcitabine in pancreatic cancer. Now, a clinically meaningful benefit has been shown for the addition of nab-paclitaxel.
  • ClinicalThought Discussions

    How Pomalidomide May Change the Way We Treat Relapsed/Refractory Myeloma

    William I. Bensinger MD - 3/27/2013 1 comment / Last Comment: 4/25/2013
    This third-generation immunomodulatory drug may soon be available for use in the clinic. Here are some of the latest data supporting its potential use in 2013 and beyond.
  • ClinicalThought Discussions

    Antigen-Based Vaccines: Will This Provide an Improvement in Standard of Care for Patients With Lung Cancer?

    Corey J. Langer MD, FACP - 3/27/2013 1 comment / Last Comment: 4/25/2013
    Although promising, several unanswered questions must be addressed to make the use of vaccines in the treatment of lung cancer a reality.
  • ClinicalThought Discussions

    How I Use Abiraterone in Metastatic CRPC: A Case Illustration

    Howard (Jack) West MD - 3/22/2013 17 comments / Last Comment: 5/5/2013
    For patients who are poor candidates for chemotherapy or disinclined to pursue it, abiraterone makes a lot of sense. In this post, I describe my approach to a 77-year-old patient who is fit but, nevertheless, wary of receiving chemotherapy
  • ClinicalThought Discussions

    Supportive Care for Patients With MM: The 5 Issues Worth Paying Attention To

    Amitabha Mazumder MD - 3/13/2013 3 comments / Last Comment: 4/12/2013
    Supportive care in MM remains a challenge, despite the development of new drugs. I offer my perspective on the key issues that need to be managed to reduce morbidity and improve treatment outcomes in MM.
10 of 47 Shown
Show 10 More
Loading...  

Filter Content By

Topic:
Subtopic:
Content type:
Conference only:
Available for credit:
Credit type:
Languages:
Author:
Jointly sponsored/coprovided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
 
Educational grants provided by:
Educational grants support only the CME-certified components of this program.

CME-Certified Module

ClinicalThought™: Oncology Highlights
Earn CME/CE credit by reviewing the Highlights module.

Latest Comments